phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion (vol 10, pg 28, 2012)

被引：0
|
作者：
Hamilton, Erika [1 ]
Blackwell, Kimberly [1 ]
Hobeika, Amy C. [2 ]
Clay, Timothy M. [3 ]
Broadwater, Gloria [4 ]
Ren, Xiu-Rong [5 ]
Chen, Wei [5 ]
Castro, Henry [3 ]
Lehmann, Frederic [3 ]
Spector, Neil [1 ]
Wei, Junping [6 ]
Osada, Takuya [6 ]
Lyerly, H. Kim [2 ]
Morse, Michael A. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Surg, Div Gen Surg, Durham, NC 27710 USA
[3] GlaxoSmithKline Biol, Rixensart, Belgium
[4] Duke Canc Inst, Canc Stat Ctr, Durham, NC USA
[5] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA
[6] Duke Univ, Med Ctr, Dept Surg, Div Surg Sci, Durham, NC 27710 USA
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷
关键词：
D O I：
10.1186/1479-5876-11-82
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients
    Berzofsky, Jay A.
    Wood, Lauren V.
    Maeng, Hoyoung
    Trepel, Jane
    Stroncek, David
    Morris, John C.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [22] Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
    Osumi, H.
    Wakatsuki, T.
    Yamamoto, N.
    Ooki, A.
    Chin, K.
    Shoji, H.
    Ogura, M.
    Nakayama, I.
    Hirano, H.
    Hara, H.
    Minashi, K.
    Shinozaki, E.
    Kato, K.
    Kitano, S.
    Takeuchi, K.
    Boku, N.
    Yamaguchi, K.
    Takahari, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S897 - S897
  • [23] A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
    Chalasani, Pavani
    Marron, Marilyn
    Roe, Denise
    Clarke, Kathryn
    Iannone, Maria
    Livingston, Robert B.
    Shan, Joseph S.
    Stopeck, Alison T.
    CANCER MEDICINE, 2015, 4 (07): : 1051 - 1059
  • [24] Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] A PHASE 1, FIRST-IN-HUMAN (FIH) CLINICAL TRIAL OF THE ANTI-HER2 CAR MACROPHAGE CT-0508 IN PARTICIPANTS WITH HER2 OVEREXPRESSING SOLID TUMORS
    Reiss, Kim
    Yuan, Yuan
    Ueno, Naoto
    Johnson, Melissa
    Dees, E. Claire
    Angelos, Mathew
    Chao, Joseph
    Gill, Saar
    Shestova, Olga
    Serody, Jonathan
    Priceman, Saul
    Ronczka, Amy
    Qureshi, Rehman
    Sonawane, Poonam
    Cushing, Daniel
    Barton, Debora
    Klichinsky, Michael
    Condamine, Thomas
    Swaby, Ramona
    Abdou, Yara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A665 - A665
  • [26] Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H-Y.
    Wu, Y-L.
    Gibson, N. J.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S63 - S64
  • [27] Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    CANCER RESEARCH, 2023, 83 (08)
  • [28] HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
    Ahmed, Nabil
    Brawley, Vita
    Hegde, Meenakshi
    Bielamowicz, Kevin
    Kalra, Mamta
    Landi, Daniel
    Robertson, Catherine
    Gray, Tara L.
    Diouf, Oumar
    Wakefield, Amanda
    Ghazi, Alexia
    Gerken, Claudia
    Yi, Zhongzhen
    Ashoori, Aidin
    Wu, Meng-Fen
    Liu, Hao
    Rooney, Cliona
    Dotti, Gianpietro
    Gee, Adrian
    Su, Jack
    Kew, Yvonne
    Baskin, David
    Zhang, Yi Jonathan
    New, Pamela
    Grilley, Bambi
    Stojakovic, Milica
    Hicks, John
    Powell, Suzanne Z.
    Brenner, Malcolm K.
    Heslop, Helen E.
    Grossman, Robert
    Wels, Winfried S.
    Gottschalk, Stephen
    JAMA ONCOLOGY, 2017, 3 (08) : 1094 - 1101
  • [29] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+metastatic breast cancer (MBC)
    Hamilton, Erika Paige
    Yardley, Denise A.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Borges, Virginia F.
    Moulder, Stacy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and/or trastuzumab, in HER2+metastatic breast cancer (MBC)
    Hamilton, Erika
    Yardley, Denise A.
    Hortobagyi, Gabriel
    Walker, Luke
    Borges, Virginia F.
    Moulder, Stacy
    CANCER RESEARCH, 2015, 75
12345